ISELIN, N.J. (AFX) - Drug developer Pharmos Corp. said Tuesday it received British approval to conduct a study on a pain medication for use after dental surgery.
The Phase IIa clinical trial of cannabinor will take place in London with 100 male patients during the third quarter, and will test the drug's effectiveness in reducing pain in patients following dental work that involves extracting molars.
The study was approved by the Medicines and Healthcare Products Regulatory Agency and the local Ethics Committee in Britain. The goal of conducting the study on patients recovering from the dental surgery is to determine the drug's potential in treating a wide variety of pain. Other studies are planned for later in the year, the company said.
Shares of Pharmos fell 2 cents to close at $2.24 on the Nasdaq SmallCap Market.
Copyright 2006 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
© 2006 AFX News